All GLG News Analyses Filed Under: Orthopaedics

Alphatec product line will expand and increase their market share The cervical plate from Progressive is much more promising than the Trestle plate developed by Alphatec, and should increase sales and improve the cervical implant portfolio

Outcomes in patients implanted with the artificial disc compare favorably with single level ACDF after 2 years.

the use of Vertex polyaxial screws is only a minor part of the spinal implant protfolio at Medtronic (MDT:NYSE).  This should not affect the bottom line to any significant extent.

Ever since Hyaluronans (HA) have been around to lubricate the the knee, arthroplasties have declined significantly for OA. This implies that finding the precise material necessary to keep the knee capsule full will prevent further degeneration of the joint and eventually the ultimate answer to treat...

Though Forteo did  increase the BMD greater than alendronate, It did not decrease the amount of no-veterbral fractures which lead to increased morbidity and mortality.

Stem cells plus HA provide a physiologically relevant combination that has real potential in tissue repair and regenerative medicine. But the press release goes further than warranted, in implying that Chondrogen addresses the OA market as a whole. The trial specifically evaluated the effects of the...

First of all, this is not a hypothesis generating study but a fishing expedition after an orthopedic procedure intervention. Maybe that's what happens when you let orthopedists loose with statistical analysis. Patients entered the study without any baseline osteoarthritis (OA) required...just a torn...

Possible nonoperative treatment for arthritis of the knee which effects 10's of millions of patients, with a predictable lasting effect. Could revolutionize the treatment of arthritis which currently has no predictable, lasting  nonoperative treatments.

Bone density loss a known risk with exogenous corticosteroid therapy...but also sex, age, disuse, catabolic disease should factor into outcome risk for fractures as the feared outcome. Forteo(R) is currently a second line therapy for osteoporosis issues based on  cost and osteosarcoma theoretical...

We know that PTH is a strong anabolic agent in the bone.  This study provides some quantitation in a head to head study of Forteo (Lilly) with Fosamax (Merck) in a population of steroid-induced osteoporosis patients.